oxiracetam has been researched along with Disease Models, Animal in 8 studies
oxiracetam: structure in first source
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The in vitro study used a cell injury controller to damage SH-SY5Y cells and evaluate the effect of oxiracetam at a dosage of 100 nM." | 1.91 | Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury. ( Cho, SM; Choi, H; Han, SW; Hong, EP; Jeon, JP; Jung, H; Kim, JT; Kim, N; Lee, A; Lee, Y; Park, CH; Youn, DH, 2023) |
| "Oxiracetam (ORC) was used as a positive drug in this experiment." | 1.62 | Poria cocos polysaccharide attenuates damage of nervus in Alzheimer's disease rat model induced by D-galactose and aluminum trichloride. ( Jiang, Y; Ling, Y; Zhang, Y; Zhou, C; Zhou, X, 2021) |
| "Oxiracetam (ORC) is a commonly used nootropic drug for improving cognition and memory impairments." | 1.51 | Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway. ( Dong, Y; Jiang, X; Liu, Z; Lv, P; Qi, Q; Xu, J, 2019) |
| "Oxiracetam is a nootropic drug that is commonly used to treat cognitive deficits of cerebrovascular origins." | 1.46 | (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. ( Guo, Y; Jiang, H; Li, W; Liu, H; Nie, Z; Pu, X; Sun, Y; Wang, C; Xiong, X; Zhang, K; Zhang, X; Zhao, X, 2017) |
| "Oxiracetam is a nootropic drug that improves clinical outcomes for some central nervous system (CNS) disorders." | 1.43 | Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats. ( Li, L; Nie, L; Yao, XL; Yao, ZH; Zhang, SF, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Youn, DH | 1 |
| Han, SW | 1 |
| Kim, JT | 1 |
| Choi, H | 1 |
| Lee, A | 1 |
| Kim, N | 1 |
| Jung, H | 1 |
| Hong, EP | 1 |
| Park, CH | 1 |
| Lee, Y | 1 |
| Cho, SM | 1 |
| Jeon, JP | 1 |
| Xu, J | 1 |
| Qi, Q | 1 |
| Lv, P | 1 |
| Dong, Y | 1 |
| Jiang, X | 1 |
| Liu, Z | 1 |
| Zhou, X | 1 |
| Zhang, Y | 1 |
| Jiang, Y | 1 |
| Zhou, C | 1 |
| Ling, Y | 1 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Wang, C | 1 |
| Guo, Y | 1 |
| Sun, Y | 1 |
| Zhao, X | 1 |
| Xiong, X | 1 |
| Zhang, X | 1 |
| Zhang, K | 1 |
| Nie, Z | 1 |
| Pu, X | 1 |
| Yao, XL | 1 |
| Yao, ZH | 1 |
| Li, L | 1 |
| Nie, L | 1 |
| Zhang, SF | 1 |
| Amano, M | 1 |
| Goto, A | 1 |
| Takahashi, N | 1 |
| Hasegawa, T | 1 |
| Nabeshima, T | 1 |
8 other studies available for oxiracetam and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Caspases; Cognitive Dysfunction; Cyclo | 2023 |
Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway.
Topics: Animals; Apoptosis; Autophagy; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; Ma | 2019 |
Poria cocos polysaccharide attenuates damage of nervus in Alzheimer's disease rat model induced by D-galactose and aluminum trichloride.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Apoptosis; Behavior, Animal; Cognition; Cognitive Dys | 2021 |
(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Astrocytes; Cerebral Cortex; Cerebrovascular Circulat | 2017 |
Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats.
Topics: Animals; Cerebrovascular Disorders; Cognitive Dysfunction; Disease Models, Animal; Male; Nootropic A | 2016 |
Effects of BMY-21502 on anoxia in mice.
Topics: Animals; Atmospheric Pressure; Benzoquinones; Brain Ischemia; Disease Models, Animal; Hypoxia, Brain | 1993 |